BR0316364A - Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer - Google Patents
Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncerInfo
- Publication number
- BR0316364A BR0316364A BR0316364-4A BR0316364A BR0316364A BR 0316364 A BR0316364 A BR 0316364A BR 0316364 A BR0316364 A BR 0316364A BR 0316364 A BR0316364 A BR 0316364A
- Authority
- BR
- Brazil
- Prior art keywords
- gst
- therapy
- anticancer
- compound
- activated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 230000001093 anti-cancer Effects 0.000 title abstract 7
- 238000011319 anticancer therapy Methods 0.000 title abstract 5
- 238000011275 oncology therapy Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- NECZZOFFLFZNHL-XVGZVFJZSA-N (2s)-2-amino-5-[[(2r)-3-[2-[bis[bis(2-chloroethyl)amino]-oxidophosphaniumyl]oxyethylsulfonyl]-1-[[(r)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 NECZZOFFLFZNHL-XVGZVFJZSA-N 0.000 abstract 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 108700011582 TER 286 Proteins 0.000 abstract 1
- 229950000772 canfosfamide Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"COMBINAçãO DE TERAPIA DO CâNCER COM UM COMPOSTO ANTICâNCER ATIVADO COM GST E UMA OUTRA TERAPIA ANTICâNCER". A presente invenção refere-se a um método de combinação de terapia do câncer em um mamífero, especialmente um ser humano, por administração de uma quantidade terapeuticamente eficaz de um composto anticâncer ativado com GST e uma dose terapeuticamente eficaz de uma outra terapia anticâncer. Composições farmacêuticas, produtos e kits para o método. O uso de um composto anticâncer ativado com GST na produção de um medicamento para o método. Um método de potencializar uma terapia anticâncer em um mamífero, especialmente um ser humano, compreendendo a administração de uma quantidade terapeuticamente eficaz de um composto anticâncer ativado com GST ao mamífero em tratamento com a terapia anticâncer. O uso de um composto anticâncer ativado com GST na produção de um medicamento para o método. O composto anticâncer ativado com GST é de preferência um composto da Patente U.S. n<0> 5.556.942, e mais preferivelmente TLK286, especialmente como o sal de cloridrato.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42698302P | 2002-11-15 | 2002-11-15 | |
| PCT/US2003/036209 WO2004045593A2 (en) | 2002-11-15 | 2003-11-14 | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0316364A true BR0316364A (pt) | 2005-10-04 |
Family
ID=32326463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0316364-4A BR0316364A (pt) | 2002-11-15 | 2003-11-14 | Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20040138140A1 (pt) |
| EP (1) | EP1562564A2 (pt) |
| JP (2) | JP2006508980A (pt) |
| KR (1) | KR20050075018A (pt) |
| CN (2) | CN100508961C (pt) |
| AR (1) | AR042051A1 (pt) |
| AU (2) | AU2003290805A1 (pt) |
| BR (1) | BR0316364A (pt) |
| CA (1) | CA2505377A1 (pt) |
| MX (1) | MXPA05005200A (pt) |
| TW (1) | TWI323662B (pt) |
| WO (1) | WO2004045593A2 (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| EP2301533A1 (en) * | 2004-07-09 | 2011-03-30 | University of Pittsburgh | Wortmannin Analogs and Method of Using Same |
| JP4903716B2 (ja) * | 2005-01-06 | 2012-03-28 | テリック，インコーポレイテッド | トリペプチドおよびテトラペプチドチオエーテル |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| US20100310661A1 (en) * | 2007-07-16 | 2010-12-09 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
| JP5688840B2 (ja) | 2007-09-10 | 2015-03-25 | ボストン バイオメディカル， インコーポレイテッド | 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤 |
| EP2249827A4 (en) * | 2008-02-08 | 2012-05-30 | Poniard Pharmaceuticals Inc | USE OF PICOPLATIN AND CETUXIMAB IN THE TREATMENT OF COLORECTAL CANCER |
| US20110021618A1 (en) * | 2008-03-25 | 2011-01-27 | Paloma Pharmaceuticals, Inc. | Methods of treating fibrotic disorders |
| WO2010086964A1 (ja) * | 2009-01-28 | 2010-08-05 | 株式会社 静岡カフェイン工業所 | がん治療のための併用療法 |
| EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| WO2012075211A2 (en) * | 2010-12-01 | 2012-06-07 | Niiki Pharma Inc. | Combination therapy with a gallium complex |
| US9381187B2 (en) | 2011-02-16 | 2016-07-05 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
| US20120251496A1 (en) * | 2011-03-31 | 2012-10-04 | Telik, Inc. | Ezatiostat for treating multiple myeloma |
| MX2015014181A (es) | 2013-04-09 | 2016-05-24 | Boston Biomedical Inc | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. |
| US20170080093A1 (en) * | 2013-10-22 | 2017-03-23 | Tyme, Inc. | Tyrosine Derivatives And Compositions Comprising Them |
| CA2955384C (en) * | 2014-07-17 | 2024-03-12 | Biocurity Holdings, Inc. | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
| US11389536B2 (en) | 2015-07-17 | 2022-07-19 | BioCurity Pharmaceuticals Inc. | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
| WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| CN110062633A (zh) * | 2016-11-30 | 2019-07-26 | 迪美公司 | 酪氨酸衍生物以及包含所述酪氨酸衍生物的组合物 |
| CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| US12037917B2 (en) * | 2020-09-28 | 2024-07-16 | Mitsubishi Heavy Industries, Ltd. | Steam turbine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599903A (en) * | 1992-04-03 | 1997-02-04 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
| US5545621A (en) * | 1991-04-29 | 1996-08-13 | Terrapin Technologies, Inc. | Glutathione S-transferase-activated compounds |
| US5556942A (en) * | 1991-04-29 | 1996-09-17 | Terrapin Technologies, Inc. | Glutathione S-transferase-activated compounds |
| US5955432A (en) * | 1992-04-03 | 1999-09-21 | Terrapin Technologies, Inc. | Metabolic effects of certain glutathione analogs |
| US5767147A (en) * | 1995-04-21 | 1998-06-16 | The Regents Of The University Of California | Inhibition of glutathione transferase by haloenol lactones |
| DE69633722T2 (de) * | 1995-06-07 | 2005-11-03 | TELIK, INC., Palo Alto | Stoffwechseleffekt von bestimmten glutation analogen |
| US5880097A (en) * | 1996-01-04 | 1999-03-09 | Terrapin Techologies, Inc. | Tethered prodrugs |
| US20030073837A1 (en) * | 1998-12-31 | 2003-04-17 | Langecker Peter J. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| GB9909925D0 (en) * | 1999-04-29 | 1999-06-30 | Pharmacia & Upjohn Spa | Combined preparations comprising anthracycline derivatives |
| CA2400197A1 (en) * | 2000-02-17 | 2001-08-23 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| CA2432792C (en) * | 2000-12-22 | 2012-04-03 | Bristol-Myers Squibb Company | Methods for modulating tumor growth and metastasis |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
-
2003
- 2003-11-13 TW TW092131777A patent/TWI323662B/zh not_active IP Right Cessation
- 2003-11-14 MX MXPA05005200A patent/MXPA05005200A/es active IP Right Grant
- 2003-11-14 AU AU2003290805A patent/AU2003290805A1/en not_active Abandoned
- 2003-11-14 AR ARP030104215A patent/AR042051A1/es not_active Application Discontinuation
- 2003-11-14 EP EP03783388A patent/EP1562564A2/en not_active Withdrawn
- 2003-11-14 CN CNB2003801034043A patent/CN100508961C/zh not_active Expired - Fee Related
- 2003-11-14 CA CA002505377A patent/CA2505377A1/en not_active Abandoned
- 2003-11-14 CN CN2009101430576A patent/CN101590229B/zh not_active Expired - Fee Related
- 2003-11-14 US US10/714,593 patent/US20040138140A1/en not_active Abandoned
- 2003-11-14 KR KR1020057008697A patent/KR20050075018A/ko not_active Ceased
- 2003-11-14 BR BR0316364-4A patent/BR0316364A/pt not_active IP Right Cessation
- 2003-11-14 WO PCT/US2003/036209 patent/WO2004045593A2/en not_active Ceased
- 2003-11-14 JP JP2004553614A patent/JP2006508980A/ja active Pending
-
2007
- 2007-10-15 US US11/872,659 patent/US20080159980A1/en not_active Abandoned
-
2010
- 2010-02-10 AU AU2010200483A patent/AU2010200483A1/en not_active Abandoned
- 2010-07-16 JP JP2010162154A patent/JP2010265305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1562564A2 (en) | 2005-08-17 |
| CN1711076A (zh) | 2005-12-21 |
| AU2003290805A1 (en) | 2004-06-15 |
| KR20050075018A (ko) | 2005-07-19 |
| JP2006508980A (ja) | 2006-03-16 |
| TW200412933A (en) | 2004-08-01 |
| CA2505377A1 (en) | 2004-06-03 |
| US20080159980A1 (en) | 2008-07-03 |
| WO2004045593A2 (en) | 2004-06-03 |
| US20040138140A1 (en) | 2004-07-15 |
| AU2010200483A1 (en) | 2010-03-04 |
| CN101590229B (zh) | 2012-12-05 |
| TWI323662B (en) | 2010-04-21 |
| AR042051A1 (es) | 2005-06-08 |
| CN100508961C (zh) | 2009-07-08 |
| MXPA05005200A (es) | 2005-08-18 |
| WO2004045593A3 (en) | 2004-08-12 |
| CN101590229A (zh) | 2009-12-02 |
| JP2010265305A (ja) | 2010-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0316364A (pt) | Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer | |
| BRPI0511296A (pt) | sensibilização à outra terapia anticáncer e/ou melhora de um efeito colateral de outra terapia anticáncer por tratamento com um composto anticáncer ativado por gst | |
| BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| BRPI0411451A (pt) | formas de dosagens orais de memantina | |
| BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
| BRPI0407897A (pt) | derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios | |
| BRPI0411024A (pt) | métodos para induzir a eritropoiese intensificada ou completa em um paciente, para tratar ou prevenir doenças, e para aumentar a produção da eritropoietina na presença de uma citocina em um paciente, uso de um composto, kit, e, composição farmacêutica | |
| BRPI0410306A (pt) | métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit | |
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BRPI0409427A (pt) | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo | |
| TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
| BRPI0412919A (pt) | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos | |
| ZA202210355B (en) | Compositions and therapeutic uses of cannabidiol | |
| BRPI0409796A (pt) | uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina | |
| IL164564A0 (en) | Combination therapy for the treatment of cancer | |
| AR065582A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
| DE602007012904D1 (de) | Neue 2',3'-methylidenacetyladenosine prodrugs zur | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BR112014004339A2 (pt) | suspensão oral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2280 DE 16/09/2014. |